Drug Price Trends for ALBENZA

Best Wholesale Price for ALBENZA

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
ALBENZA 200MG TAB	Amneal Pharmaceuticals of New York, LLC	64896-0693-49	2	40.25	20.12500	EACH	2022-09-27 - 2027-06-30	Big4
ALBENZA 200MG TAB	Amneal Pharmaceuticals of New York, LLC	64896-0693-49	2	478.02	239.01000	EACH	2022-09-27 - 2027-06-30	FSS
ALBENZA 200MG TAB	Amneal Pharmaceuticals of New York, LLC	64896-0693-49	2	43.55	21.77500	EACH	2023-01-01 - 2027-06-30	Big4
ALBENZA 200MG TAB	Amneal Pharmaceuticals of New York, LLC	64896-0693-49	2	478.02	239.01000	EACH	2023-01-01 - 2027-06-30	FSS

ALBENZA Market Analysis and Price Projections

Last updated: February 17, 2026

This report analyzes the market dynamics and price projections for ALBENZA (albendazole) for the period 2024-2029. The analysis focuses on its therapeutic applications, competitive landscape, patent status, and regulatory environment to inform R&D and investment decisions.

What is the Current Market Size and Growth Trajectory for ALBENZA?

ALBENZA, an anthelminthic medication, primarily treats various parasitic worm infections. Its market is intrinsically linked to the prevalence of these infections globally, particularly in regions with poor sanitation and limited access to clean water.

The global market for anthelminthic drugs, including albendazole-based products like ALBENZA, is projected to reach approximately USD 4.5 billion by 2028, growing at a compound annual growth rate (CAGR) of 3.8% from 2023 [1]. This growth is driven by increased public health initiatives aimed at controlling neglected tropical diseases (NTDs), improved diagnostics, and the continuous need for mass deworming programs, especially in endemic areas.

ALBENZA's specific market share is influenced by its formulation, brand recognition, and the presence of generic alternatives. In established markets, its penetration is sustained by physician prescription patterns and formulary inclusions. In emerging markets, affordability and accessibility are key determinants of market penetration, often leading to a preference for lower-cost generic albendazole products.

What are the Primary Therapeutic Indications for ALBENZA?

ALBENZA is indicated for the treatment of the following parasitic infections:

• Neurocysticercosis: A tapeworm infection of the brain and nervous system.
• Hydatid disease: A parasitic infection caused by the tapeworm Echinococcus granulosus.
• Intestinal worm infections: Including ascariasis (roundworm), hookworm, trichuriasis (whipworm), and strongyloidiasis.
• Giardiasis: An infection of the small intestine caused by the protozoan parasite Giardia lamblia.

The sustained prevalence of these infections, particularly in developing countries, ensures a consistent demand for effective treatments like ALBENZA. WHO estimates indicate that over 1.5 billion people worldwide are infected with at least one of the major soil-transmitted helminths [2].

Who are the Key Market Competitors for ALBENZA?

The competitive landscape for ALBENZA is characterized by both branded and generic products. The primary competitors include:

• Other Albendazole Formulations: Various pharmaceutical companies market albendazole under different brand names, offering comparable efficacy and safety profiles.
• Mebendazole: Another broad-spectrum benzimidazole anthelminthic, often used for similar intestinal worm infections. Mebendazole is widely available and generally more affordable than branded albendazole.
• Praziquantel: Primarily used for tapeworm and fluke infections, including schistosomiasis. It competes in specific indication areas.
• Ivermectin: While primarily known as an anti-parasitic for veterinary use and certain human filarial infections, it can overlap with ALBENZA's indications in some parasitic diseases.
• Pyrantel Pamoate: Commonly used for pinworm, roundworm, and hookworm infections, often available over-the-counter.

The market is highly sensitive to price, with generic albendazole and other cost-effective anthelminthics posing significant competition, particularly in price-sensitive emerging markets.

What is the Patent and Exclusivity Status of ALBENZA?

The original patents for albendazole have long since expired. ALBENZA, as a branded product, may have had patent protection for specific formulations, manufacturing processes, or new indications at various times. However, currently, the active pharmaceutical ingredient (API) albendazole is off-patent.

• API Patent Expiry: Albendazole's basic patent expired decades ago.
• Formulation Patents: Any patents related to specific ALBENZA formulations (e.g., improved bioavailability, novel delivery systems) would have their own expiry dates. Information on current formulation patents would require a detailed patent landscape search.
• Exclusivity Periods: Regulatory exclusivity, such as data exclusivity or market exclusivity granted for new drug applications (NDAs) or supplemental new drug applications (SNDAs) in regions like the U.S., would have also expired for the original approvals.

The absence of strong patent protection for the API means that the market is open to generic competition once regulatory exclusivities for branded formulations have lapsed. This significantly impacts pricing strategies and market exclusivity for the originator product.

What are the Key Regulatory Considerations and Approvals for ALBENZA?

ALBENZA (albendazole) is approved by major regulatory bodies worldwide.

• U.S. Food and Drug Administration (FDA): Albendazole is approved for the treatment of neurocysticercosis and hydatid disease. It is also used off-label for various intestinal nematode infections. The original New Drug Application (NDA) would have been approved decades ago.
• European Medicines Agency (EMA): Albendazole is authorized in European Union member states for similar indications.
• World Health Organization (WHO): Albendazole is on the WHO Model List of Essential Medicines [3], underscoring its importance in global public health and its frequent use in mass drug administration programs for NTDs.
• Other Regulatory Authorities: Approvals exist in numerous countries, often aligned with WHO guidelines and local disease prevalence.

Regulatory hurdles primarily concern manufacturing standards (Good Manufacturing Practices - GMP), quality control, and pharmacovigilance. For new market entries or expanded indications, manufacturers must meet the specific requirements of each national regulatory agency. The availability of generic albendazole is widespread due to its inclusion on essential medicines lists and its long history of use.

What are the Price Trends and Projections for ALBENZA?

The pricing of ALBENZA is influenced by several factors, including brand positioning, generic competition, market access, and the volume of sales through public health programs.

• Branded ALBENZA: Prices for branded ALBENZA (e.g., Eskazole® by GlaxoSmithKline, though its status as the primary branded product may vary by region and over time) are typically higher than generic alternatives. Prices can range from USD 10 to USD 50 per treatment course, depending on the formulation strength, pack size, and geographic market.
• Generic Albendazole: Generic albendazole is significantly more affordable, with prices often ranging from USD 0.50 to USD 5 per treatment course. This price difference is a major driver of market share in endemic regions and for large-scale public health interventions.
• Public Health Programs: For mass deworming initiatives funded by governments or international organizations (e.g., WHO, UNICEF), the price of albendazole is negotiated at very low rates, often in the cents per dose range. These programs represent a substantial volume but at lower per-unit revenue.

Price Projections (2024-2029):

• Developed Markets: Prices for branded ALBENZA are expected to remain relatively stable, with potential modest increases due to inflation and R&D investments in new formulations or delivery methods. However, physician preference for generics in some indications, where efficacy is comparable, may cap significant price growth.
• Emerging Markets: Prices for both branded and generic ALBENZA are likely to face downward pressure due to intense generic competition and the preference for the lowest cost options. Public health procurement will continue to drive high-volume, low-price sales.
• Overall Trend: The overall average selling price (ASP) for albendazole products globally is projected to decline slightly due to the increasing dominance of low-cost generics and the substantial volume of sales through price-sensitive public health programs. The CAGR for the overall albendazole market price is projected to be in the negative low single digits (-1% to -2%) over the next five years.

Key Factors Influencing Future Pricing:

• Generic Entry and Competition: Continued proliferation of generic albendazole manufacturers will intensify price competition.
• Public Health Procurement: The volume and pricing negotiated by large NGOs and government bodies for NTD programs will significantly influence global average pricing.
• Regulatory Landscape: Changes in regulatory requirements for generics or new marketing authorizations could impact market entry and pricing.
• Disease Prevalence: While stable, significant shifts in the prevalence of target parasitic infections could alter demand and pricing dynamics.
• New Indications or Formulations: Development of novel albendazole formulations with improved efficacy, safety, or patient compliance could command premium pricing, but such developments are not currently prominent in public domain research.

What are the Market Opportunities and Challenges for ALBENZA?

Opportunities:

• Underserved Populations: Significant unmet needs persist in low-income countries for widespread access to essential anthelminthics. ALBENZA, particularly in generic form, can address this.
• Neglected Tropical Diseases (NTDs) Initiatives: Continued global and national efforts to control NTDs will drive demand for mass deworming campaigns, a core application for albendazole.
• Combination Therapies: Research into combination therapies for resistant parasitic strains or broader spectrum coverage could create new market niches.
• Veterinary Applications: While this analysis focuses on human use, albendazole is also a widely used veterinary anthelminthic, representing a related but distinct market.

Challenges:

• Intense Generic Competition: The off-patent status of albendazole API leads to a highly competitive generic market, eroding profit margins for branded products.
• Price Sensitivity: The primary market segments are highly price-sensitive, limiting revenue potential for premium-priced products.
• Limited Innovation: The drug has been in use for decades, and significant breakthroughs in new formulations or mechanisms of action are not currently prevalent.
• Drug Resistance: While not a widespread issue for albendazole currently, the emergence of resistance in parasitic populations is a long-term threat that could impact efficacy and market demand for older anthelminthics.
• Shifting Disease Burden: Changes in global health priorities or improvements in sanitation and public health infrastructure in endemic regions could alter the prevalence of target infections.

Key Takeaways

ALBENZA operates in a mature market segment dominated by generic competition. While branded formulations exist, their pricing power is constrained by the widespread availability of significantly cheaper generic albendazole. The market is driven by the ongoing prevalence of parasitic infections globally, particularly in developing nations, and is heavily influenced by public health initiatives and mass deworming programs. Future price projections indicate a continued decline in average selling prices due to the volume of low-cost generic sales, with branded products facing limited growth opportunities unless novel formulations or expanded indications emerge.

Frequently Asked Questions

1. What is the primary driver of ALBENZA sales volume?

The primary driver of ALBENZA sales volume is the global prevalence of parasitic worm infections, particularly in low- and middle-income countries, coupled with large-scale public health deworming programs.

2. How does the cost of generic albendazole compare to branded ALBENZA?

Generic albendazole is substantially more affordable than branded ALBENZA, with treatment courses for generics often costing less than USD 5, while branded versions can range from USD 10 to USD 50 per course.

3. Are there any significant new therapeutic indications for ALBENZA currently in development?

As of current publicly available research, there are no widespread, significant new therapeutic indications for ALBENZA in late-stage development that are poised to dramatically alter its market.

4. What is the typical duration of treatment for infections treated with ALBENZA?

Treatment duration for infections treated with ALBENZA varies by the type of parasitic infection. For intestinal nematodes, treatment is often a single dose or a short course of 1-3 days. For conditions like hydatid disease or neurocysticercosis, treatment can be prolonged, spanning several months or even years.

5. How does ALBENZA's patent status affect its market price and availability?

The expiration of albendazole's primary patents means the active pharmaceutical ingredient is available to any manufacturer. This has led to widespread generic production, driving down prices and increasing market availability globally.

Citations

[1] Grand View Research. (2023). Anthelmintic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Benzimidazoles, Avermectins, Nicotinic Acid Derivatives, Organophosphates), By Application (Human, Veterinary), By Region, And Segment Forecasts, 2023 - 2030. [2] World Health Organization. (2023, November 14). Soil-transmitted helminths. Retrieved from https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminths [3] World Health Organization. (2023). World Health Organization model list of essential medicines: 23rd list 2023.